Genmab (Danish) invents antibody cancer drugs, earning royalties on Darzalex.
Genmab A/S (GMAB) is expected to report earnings on Thursday, November 5, 2026, after the close. Consensus EPS estimate is $0.36.
| Report date | Quarter | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|---|
| 2026-08-06 | FY2026 Q2 | $0.37 | $0.49 | +32.4% | $1.16B |
| 2026-05-07 | FY2026 Q1 | $0.15 | $0.09 | -42.0% | $899.32M |
| 2025-08-07 | FY2025 Q2 | $0.39 | $0.54 | +38.5% | $924.81M |
| 2025-05-08 | FY2025 Q1 | $0.23 | $0.04 | -80.4% | $105.23M |
| 2025-11-06 | FY2024 Q4 | $0.48 | $0.65 | +35.4% | $1.02B |
| 2024-08-08 | FY2024 Q2 | $0.29 | $0.32 | +10.3% | $779.00M |
| 2023-11-07 | FY2023 Q3 | $3.14 | $3.26 | +3.8% | — |
| 2023-08-03 | FY2023 Q2 | $2.18 | $2.08 | -4.6% | — |
GMAB has beaten consensus EPS in 5 of its last 8 reported quarters.
GMAB reported Aug 6. The highlights: EPS of $0.49 — a big beat vs the $0.37 estimate (+32%); revenue of $1.16B — a beat vs the $1.12B consensus (+3%). Focus now shifts to royalty transitions and pipeline.
See GMAB on the live calendar →